Tag:
stem cell
Latest Headlines
Latest Headlines
VistaGen raises $36M for stem cell tech
The biotech says it will use the cash to "accelerate and expand its stem cell technology-based drug rescue programs."
Gentium shares wrecked by fresh round of regulatory woes for lead drug
Shares of Italy's Gentium plunged more than 40% this morning after the biotech announced a fresh round of woes with regulators--this time in Europe--for its vascular drug defibrotide.
Lentigen's stem cell delivery for brain tumors nets FDA orphan status
The FDA awarded orphan drug status to Lentigen's brain tumor stem cell treatment that protects healthy cells from a particularly toxic cancer drug. The orphan drug designation, an incentive for companies developing treatments for rare diseases, allows for 7 years of market exclusivity.
Stem cell developer reveals second patient death as criticism builds
Pluristem Therapeutics ($PTSI) fired off a press release yesterday demanding corrections to a Bloomberg article this week about the company's stock sale that followed the undisclosed death of a patient who got the biotech's experimental stem cell therapy. Below the demand, in its statement, the company let loose another important detail: That not one, but two of three patients who received its therapy under compassionate use guidelines died after treatment.
After cashing in on life-saving boast, biotech stayed mum on patient death
Back in August, Israel's Pluristem Therapeutics ($PSTI) breathlessly announced that its stem cell therapy had saved the life of a 54-year-old woman teetering on the brink of death. A clinical investigator was quoted in the company's release calling the intervention with its PLX cells a "real breakthrough," coming just months after another life-saving intervention with a 7-year-old.
Ex-Geron chief spearheads bid to revive mothballed stem cell studies
Back in early 2011 Geron CEO Thomas Okarma was forced to step aside as the biotech prepared to bring in a new CEO to restructure the operations. Now Okarma is back, leading a new regenerative medicine venture set up by BioTime. And he wants his stem cell work back.
Stem cell pioneers win this year's Nobel Prize for medicine
Five years after Shinya Yamanaka at Kyoto University shook the R&D world with the news that he had converted mature cells into embryonic-like stem cells, the Nobel committee has awarded him one of this year's prestigious prizes for medicine.
Feds win guilty pleas from two men in stem cell therapy scam
Frank Morales and Lawrence Stowe face jail time for their scam, which the TV show "60 Minutes" covered with hidden cameras back in April 2010, according to a CBS News report.
Geron in meltdown as lead cancer drug crumbles in Phase II
Just 10 months after new Geron CEO John Scarlett dumped a decade's worth of stem cell work in favor of a special focus on cancer drugs, the biotech has written off a pair of lead drug studies after tracking discouraging progression-free survival data in Phase II.
Melanoma stem cells may carry provocative drug target
Melanoma stem cells are marked by a particular enzyme that could serve as a potent new target for treatment, a University of Colorado Cancer Center study concludes.
